Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-CD25 Monoclonal Antibody vs Methotrexate for Acute GVHD Prevention
NCT07689630Phase 3Recruiting
- Start
- May 2026
- Primary completion
- May 2028
- Countries
- 1
01
Overview
A Phase 3 trial of daclizumab in graft-versus-host disease (GVHD). Started May 2026; status: recruiting.
02
Drugs
daclizumab
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT07689630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07689630.